Leukogene Therapeutics Highlights MHC Class II-Engager Platform in AACR 2026 Presentations for AML and Pancreatic Cancer
Leukogene Therapeutics presents two posters at AACR 2026 showcasing its proprietary M2T platform, designed to harness MHC class II-engaging mechanisms to redirect immune response against acute myeloid leukemia and pancreatic cancer. CEO Sandeep Gupta framed the platform as targeting two of the most lethal and treatment-resistant cancers. Posters appear in the Bi- and Tri-Specific Antibody Therapies session on April 21.